Pommier

(GETUG-01)

[24]

1998-2004

444

T1b-T3, N0 pNx, M0

21%- low risk (<15%- Roach)

4 - 8 months NHT, plus concurrent ADT mandatory for high risk

Prostate and pelvis

66 - 70 Gy to the prostate and SV, 44 - 46 Gy to the pelvis

No difference between pelvic and PO RT

10-year OS (74.9% vs 73.6%), or EFS

(57.6% vs 55.6%)

Mottet

[36]

2000-2003

264

T3-4 or pT3N0M0

3yrs ADT

Prostate and pelvis

68 - 70 Gy to the prostate and SV, 46 Gy to pelvic nodes

5 year PFS in favour of ADT + RT vs ADT alone (64.7% vs 15.4%,p < 0.001)

Blanchard

(GETUG-12)

[26]

2002-2006

413

At least 1 of the following high-risk features: Gleason score > 8, stage T3 or T4 disease, serum PSA concentration >20 ng/mL or pN+

3 years ADT

plus 4 cycles of Docetaxel Estramustine

Prostate

(n-208)

74 Gy-prostate and SV

Prostate and pelvis

(n-150)

74 Gy-prostate and SV

46 - 50 Gy to the pelvis

Median follow-up was 8.8 years.

No association between bPFS and use of pelvic ENI in multivariate analysis (HR: 1.10 [95% CI: 0.78 - 1.55], p = .60), even when analysis was restricted to pN0 patients (HR: 0.88 [95% CI: 0.59 - 1.31], p = .53)

Morris

(ASCENDE-RT)

[27]

2004-2011

398

At least 1 of the following high-risk features: Gleason score >8, serum PSA concentration > 20 ng/mL

Excluded if T3b or greater, N1, or PSA > 40

12 months ADT

Prostate and pelvis

EBRT 46 Gy to pelvis then randomized to receive DE-EBRT-78 Gy or LDR-PB

At median follow-up 6.5 years

DE-EBRT twice as likely to experience biochemical failure HR 2.04

Estimated 5, 7, 9 year bPFS-89%, 86%, 83% (LDR-PB) vs 84%, 75% 62% (DE-EBRT) respectively